Liraglutide — Indexed Studies

Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis.

Dong R, Gu L, Li H et al.

Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Gao W, Cai X, Wang X et al.

Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.

Zhou G, Liu A, Hu X et al.

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.

Galindo RJ, Gudzune KA, Look M et al.

Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.

Wolsing SK, Dogan ADA, Juhl CB et al.

A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.

Joshi S, Das AK, Khunti K et al.

Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.

Ciudin A, Sapin H, Fan L et al.

Impact of Liraglutide on Insulin Clearance in Patients with Type 2 Diabetes Mellitus: Evidence from a Randomized Controlled Trial.

Boelling M, Pu J, Shen J et al.

Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.

Iglesias P, Nobre EL, Hanzu F et al.

Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.

Gaytan G, Pabon A, Rosario N

Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.

Cheng H, Jiang X, Zhu X et al.

Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.

Xu Y, Huang T, Zhang Y et al.

Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.

Almukhadeb E, Nagshabandi KN, Alshehri N et al.

Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.

Choi WS, Song MK, Seo M et al.

Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.

Van Laren J, Friesleben C, Gershovich O et al.

Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study.

Sánchez-García D, Luna-Garza Y, Saavedra-Castillo E et al.

Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.

Bai S, Wei M, Wu Y et al.

Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.

Menkü Özdemir FD, Uzun H

Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.

Mai T

Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial.

Fang W, Li Z, Xu J et al.

Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching.

Yuan Z, Jeffcoat CH, Ali SR et al.

Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.

Baldassarre MPA, Carrieri F, Coluzzi S et al.

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.

Hsiao FC, Hsu TJ, Hsieh YJ et al.

Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.

Ailawadi S, Murphy JE, Storandt MH et al.

Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report.

Mora-Bravo F, Morales PT, Pincay G et al.

Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.

Xu H, Zhang Y

Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.

Gutierrez de Piñeres V, Ramirez-Cisneros A, Tamayo-Torres CS et al.

Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Gonzalez JS, Wen H, Butera NM et al.

The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.

O'Mara A, Mody BP, Mammi M et al.

Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.

Stefanakis K, Gutierrez de Piñeres V, Veeragandham P et al.

Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.

Violante-Cumpa JR, Rios-Ortega AG, Sánchez-García A et al.

GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization.

Mahadevan A, Vosooghi A, Arora JS et al.

Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.

Myers WK, Heath G, Rohrer B

Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.

Tsironikos GI, Tsolaki V, Zakynthinos GE et al.

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Kahn SE, Tripputi M, Lachin JM et al.

Efficacy of atomoxetine and oxybutynin in the treatment of pediatric obstructive sleep apnea, a three case report.

Larramona Carrera H

RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.

Ullah H, Khan ZU, Wazir A et al.

Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.

Kassab MB, Khraishah H, Thrapp A et al.

Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.

Bergenstal RM, Crandall JP, Rosin SP et al.

Circadian rhythm-aligned time-restricted feeding prevents ovariectomy-induced fat gain, insulin resistance, and osteosarcopenia in rats.

Kulkarni C, Washimkar KR, Yadav S et al.

Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.

Prado BS, Mazzotti DR, Franci A et al.

Emulating the LEADER trial in China: a regulatory science case study on non-interventional research.

Zhao J, Xin X, Song Y et al.

GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.

Alourfi NM, Alorfi NM

A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.

Tian Y, Liu Y, Jing H et al.

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.

Wang X, Qin J, Liu Y et al.

Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects.

Prasad A, Arora A, Arora A et al.

Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.

Hindi A, Mekkawy M, Shokr H

Comparative Effectiveness of Liraglutide and Dulaglutide in Heart Failure with Preserved Ejection Fraction: A Propensity Score-Matched Real-World Study.

Khalil I, Hossain I, Sarker P et al.

Benchmarking size-exclusion chromatography columns for the analysis of therapeutic peptides and model oligonucleotides.

Buff M, Goyon A, Zhang K et al.

Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.

Lee N, Kim Y